The Endocrine Disruptor Monoethyl-hexyl-phthalate Is a Selective Peroxisome Proliferator-activated Receptor γ Modulator That Promotes Adipogenesis*
暂无分享,去创建一个
Aurélien Grosdidier | Olivier Michielin | Vincent Zoete | Yves Engelborghs | Béatrice Desvergne | W. Wahli | D. Rossi | V. Zoete | O. Michielin | R. Métivier | Cicerone Tudor | J. Feige | L. Gelman | B. Desvergne | Y. Engelborghs | Walter Wahli | A. Grosdidier | Raphaël Métivier | Jérôme N Feige | Laurent Gelman | Daniel Rossi | Cicerone Tudor | Silvia I Anghel | Caroline Lathion | S. Anghel | Caroline Lathion
[1] Aurélien Grosdidier,et al. Combined Simulation and Mutagenesis Analyses Reveal the Involvement of Key Residues for Peroxisome Proliferator-activated Receptorα Helix 12 Dynamic Behavior* , 2007, Journal of Biological Chemistry.
[2] W. Wahli,et al. Association with Coregulators Is the Major Determinant Governing Peroxisome Proliferator-activated Receptor Mobility in Living Cells* , 2007, Journal of Biological Chemistry.
[3] G. Mortier,et al. qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data , 2007, Genome Biology.
[4] Tetsuo Takahashi,et al. In vitro screening of 200 pesticides for agonistic activity via mouse peroxisome proliferator-activated receptor (PPAR)alpha and PPARgamma and quantitative analysis of in vivo induction pathway. , 2006, Toxicology and applied pharmacology.
[5] Bruce Blumberg,et al. Endocrine-disrupting organotin compounds are potent inducers of adipogenesis in vertebrates. , 2006, Molecular endocrinology.
[6] T. Fujimura,et al. A Selective Peroxisome Proliferator-Activated Receptor γ Modulator with Distinct Fat Cell Regulation Properties , 2006, Journal of Pharmacology and Experimental Therapeutics.
[7] K. Korach,et al. Endocrine-disrupting chemicals use distinct mechanisms of action to modulate endocrine system function. , 2006, Endocrinology.
[8] W. Wahli,et al. Differentiation of Trophoblast Giant Cells and Their Metabolic Functions Are Dependent on Peroxisome Proliferator-Activated Receptor β/δ , 2006, Molecular and Cellular Biology.
[9] Armin Ruf,et al. A Novel Partial Agonist of Peroxisome Proliferator-Activated Receptor-γ (PPARγ) Recruits PPARγ-Coactivator-1α, Prevents Triglyceride Accumulation, and Potentiates Insulin Signaling in Vitro , 2006 .
[10] Béatrice Desvergne,et al. From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. , 2006, Progress in lipid research.
[11] B. Blumberg,et al. New modes of action for endocrine-disrupting chemicals. , 2006, Molecular endocrinology.
[12] B. L. Bálint,et al. Selective modulators of PPAR activity as new therapeutic tools in metabolic diseases. , 2006, Endocrine, metabolic & immune disorders drug targets.
[13] Ivan Rusyn,et al. Modes of Action and Species-Specific Effects of Di-(2-ethylhexyl)Phthalate in the Liver , 2006, Critical reviews in toxicology.
[14] Michael Lehrke,et al. The Many Faces of PPARγ , 2005, Cell.
[15] R. Waring,et al. Endocrine disrupters: A human risk? , 2005, Molecular and Cellular Endocrinology.
[16] U. Kintscher,et al. Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. , 2005, Diabetes.
[17] Daniel Sage,et al. PixFRET, an ImageJ plug‐in for FRET calculation that can accommodate variations in spectral bleed‐throughs , 2005, Microscopy research and technique.
[18] M. Lazar,et al. PPARγ regulates adipocyte cholesterol metabolism via oxidized LDL receptor 1 , 2005 .
[19] Y. Chao,et al. Design and Synthesis of α-Aryloxyphenylacetic Acid Derivatives: A Novel Class of PPARα/γ Dual Agonists with Potent Antihyperglycemic and Lipid Modulating Activity , 2005 .
[20] W. Wahli,et al. Fluorescence Imaging Reveals the Nuclear Behavior of Peroxisome Proliferator-activated Receptor/Retinoid X Receptor Heterodimers in the Absence and Presence of Ligand*♦ , 2005, Journal of Biological Chemistry.
[21] J. Berger,et al. PPARs: therapeutic targets for metabolic disease. , 2005, Trends in pharmacological sciences.
[22] M. Brady,et al. The Nuclear Receptor Corepressors NCoR and SMRT Decrease Peroxisome Proliferator-activated Receptor γ Transcriptional Activity and Repress 3T3-L1 Adipogenesis* , 2005, Journal of Biological Chemistry.
[23] T. Nakanishi,et al. Organotin Compounds Promote Adipocyte Differentiation as Agonists of the Peroxisome Proliferator-Activated Receptor γ/Retinoid X Receptor Pathway , 2005, Molecular Pharmacology.
[24] M. Lazar,et al. Corepressors selectively control the transcriptional activity of PPARgamma in adipocytes. , 2005, Genes & development.
[25] J. Corton,et al. Role of PPARalpha in mediating the effects of phthalates and metabolites in the liver. , 2005, Toxicology.
[26] T. Fujimura,et al. FK614, a novel peroxisome proliferator-activated receptor gamma modulator, induces differential transactivation through a unique ligand-specific interaction with transcriptional coactivators. , 2005, Journal of pharmacological sciences.
[27] D. Lai,et al. Rodent Carcinogenicity of Peroxisome Proliferators and Issues on Human Relevance , 2004, Journal of environmental science and health. Part C, Environmental carcinogenesis & ecotoxicology reviews.
[28] J. V. Vanden Heuvel,et al. Activation of mouse and human peroxisome proliferator-activated receptors (PPARs) by phthalate monoesters. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.
[29] I. Kawamura,et al. Pharmacological characteristics of a novel nonthiazolidinedione insulin sensitizer, FK614. , 2004, European journal of pharmacology.
[30] W. Wahli,et al. Be fit or be sick: peroxisome proliferator-activated receptors are down the road. , 2004, Molecular endocrinology.
[31] G. Barish,et al. PPARs and the complex journey to obesity , 2004, Nature Medicine.
[32] Heike Brand,et al. Estrogen Receptor-α Directs Ordered, Cyclical, and Combinatorial Recruitment of Cofactors on a Natural Target Promoter , 2003, Cell.
[33] Terry Speed,et al. Normalization of cDNA microarray data. , 2003, Methods.
[34] D. Waxman,et al. Activation of PPARα and PPARγ by Environmental Phthalate Monoesters , 2003 .
[35] Charles L. Brooks,et al. New analytic approximation to the standard molecular volume definition and its application to generalized Born calculations , 2003, J. Comput. Chem..
[36] Bruce A. Johnson,et al. Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. , 2003, Molecular endocrinology.
[37] Carlos Sonnenschein,et al. Endocrine disruptors: from Wingspread to environmental developmental biology , 2002, The Journal of Steroid Biochemistry and Molecular Biology.
[38] B. Spiegelman,et al. Transcription coactivator TRAP220 is required for PPARγ2-stimulated adipogenesis , 2002, Nature.
[39] S. Dudoit,et al. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. , 2002, Nucleic acids research.
[40] J. Auwerx,et al. A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. , 2001, Molecular cell.
[41] N. Blomberg,et al. Structure of the PPARα and -γ Ligand Binding Domain in Complex with AZ 242; Ligand Selectivity and Agonist Activation in the PPAR Family , 2001 .
[42] P E Bourne,et al. The Protein Data Bank. , 2002, Nucleic acids research.
[43] David J. Waxman,et al. trans-activation of PPARα and PPARγ by structurally diverse environmental chemicals , 1999 .
[44] J. Auwerx,et al. p300 Interacts with the N- and C-terminal Part of PPARγ2 in a Ligand-independent and -dependent Manner, Respectively* , 1999, The Journal of Biological Chemistry.
[45] D. Robyr,et al. Transcriptional Regulatory Patterns of the Myelin Basic Protein and Malic Enzyme Genes by the Thyroid Hormone Receptors α1 and β1* , 1998, The Journal of Biological Chemistry.
[46] T. Willson,et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ , 1998, Nature.
[47] Alexander D. MacKerell,et al. All-atom empirical potential for molecular modeling and dynamics studies of proteins. , 1998, The journal of physical chemistry. B.
[48] R. Schulte‐Hermann,et al. Hepatocarcinogenic potential of di(2-ethylhexyl)phthalate in rodents and its implications on human risk. , 1996, Critical reviews in toxicology.
[49] T. Halgren. Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94 , 1996, J. Comput. Chem..
[50] I. Issemann,et al. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators , 1990, Nature.
[51] D. T. Williams,et al. Retention, excretion and metabolism of Di-(2-ethylhexyl) phthalate administered orally to the rat , 1974, Bulletin of environmental contamination and toxicology.